Психические расстройства в общей медицине. №4 2013

Взаимодействие основных групп противоопухолевых и психотропных препаратов, применяющихся у пациенток со злокачественными опухолями женской репродуктивной системы

М.А.Самушия

ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России

Стр. 16-22

10836 просмотров

Опубликовано: 29 декабря 2013

Аннотация / Abstract

Резюме. В целях совершенствования психофармакотерапевтической помощи пациенткам, страдающим онкологическими заболеваниями органов женской репродуктивной системы, уточнен целый ряд интеракций основных групп противоопухолевых средств, используемых в схемах адъювантной и неоадъювантной терапии этих больных, со средствами психофармакотерапии. Выделены три уровня риска нежелательного взаимодействия – высокий, средний, низкий. Даны подробные рекомендации, позволяющие оптимизировать лечебный процесс с учетом политерапевтического воздействия. Ключевые слова: интеракция, риск нежелательного взаимодействия, психофармакотерапия, противоопухолевая терапия, злокачественные новообразования органов женской репродуктивной системы. Interaction of main groups of antineoplastic and psychotropic drugs used in patients with malignant tumors of the female reproductive system M.A.Samushiya First Moscow State Medical University I.M.Sechenov Summary. For the purposes of the development of psychopharmacotherapeutical assistance for the patients, having oncology diseases of the female reproductive system organs, a large variety of interactions of the main groups of antineoplastic drugs, used in adjuvant and neoajuvant therapy schemes along with psychopharmacotherapy drugs, is specified. Three risk levels of adverse interaction (high, medium, low) are distinguished. Detailed recommendations, enabling to optimize medical treatment with account of polytherapeutic intervention, are given. Key words: interaction, adverse interaction risk, psychopharmacotherapy, anticancer therapy, cancer of the female reproductive system organs. При выборе средств психофармакотерапии для лечения психопатологических расстройств у пациенток со злокачественными новообразованиями органов женской репродуктивной системы (ЖРС) необходимо учитывать вероятность интеракции этой группы препаратов со средствами химиотерапии и гормонотерапии. В насто...

Материал для специалистов

Полный текст статьи доступен только зарегистрированным пользователям.

Вход / Регистрация

1. Baker SD. Drug interactions with the taxanes. Pharmacotherapy 1997; 17 (5 Pt. 2): s126–32.
2. Clark JM, Seager SJ. Gastric emptying following premedication with glycopyrrolate or atropine. Br J Anaesth 1983; 55: 1195–9.
3. Crewe HK, Notley LM, Wunsch RM et al. Metabolism of tamoxifen by recombinant human cytochrome P-450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dis 2002; 30: 869–74.
4. Damkier P, Hansen LL, Brosen K. Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 1999; 55: 451–6.
5. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine – An atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509–22.
6. Divoll M, Greenblatt DJ, Lacasse Y, Shader RI. Benzodiazepine overdosage: plasma concentrations and clinical outcome. Psychopharmacol Berl 1981; 73: 381–3.
7. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P-450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41–57.
8. Gabbay V, O'Dowd MA, Mamamtavrishvili M, Asnis GM. Clozapine and oral contraceptives: A possible drug interaction. J Clin Psychopharmacol 2002; 22: 621–2.
9. Gardiner JS, Blough D, Drinkard CR et al. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy 2000; 20: 1423–31.
10. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged Q–Tc interval, torsade de pointes, and sudden death. Am J Psychiat 2001; 158: 1774–82.
11. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312–8.
12. Hardman JG, Limbird LE, Gilman AG (eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed. NY: McGraw-Hill 2001.
13. Holdich T, Whiteman P, Orme M et al. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia 32 (Suppl.) 1991; 96.
14. Huyse F, van Schijndel RS. Haloperidol and cardiac arrest. Lancet 1988; 2: 568–9.
15. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the Q–Tc interval. Exp Opin Drug Saf 2002; 1: 121–8.
16. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM. Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract). Proc Ann Meet Am Assoc Cancer Res 1993; 34: a21981993.
17. Keitner GI, Fruzzetti AE, Miller IW et al. The effect of anticonvulsants on the dexamethasone suppression test. Can J Psychiat 1989; 34: 441–3.
18. Lemberger L, Rowe H, Bosomworth JC et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988; 43: 412–9.
19. Levy RH. Cytochrome P-450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36 (Suppl.) 5: s8–13.
20. Miceli JJ, Anziano RJ, Robarge L et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000; 49 (Suppl. 1): s65–70.
21. Miceli JJ, Smith M, Robarge L et al. The effects of ketoconazole on ziprasidone pharmacokinetics – a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 2000; 49 (Suppl. 1): s71–6.
22. Neef C, de Voogd-van der Straaten. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988; 43: 372–5.
23. Nimmo J, Heading RC, Tothill P, Prescott LF. Pharmacological modification of gastric emptying: effects of propantheline and metoclopramide on paracetamol absorption. Br Med J 1973; 1: 587–9.
24. O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann Pharmacother 1999; 33: 1046–9.
25. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41: 706–13.
26. Oren DA. Dysphoria after treatment with ondansetron. Am J Psychiat 1995; 152: 1101.
27. Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 1999; 40 (Suppl. 10): s48–56.
28. Plushner SL. Valerian: valeriana officinalis. Am J Health Syst Pharm 2000; 57: 328–35.
29. Prakash C, Kamel A, Cui D et al. Identification of the major human liver cytochrome P-450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 (Suppl. 1): s35–42.
30. Privitera MR, Greden JF, Gardner RW et al. Interference by carbamazepine with the dexamethasone suppresion test. Biol Psychiat 1982; 17: 611–20.
31. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187–93.
32. Simonian NA, Gilliam FG, Chiappa KH. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurol 1993; 43: 2700–2.
33. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794–847.
34. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4–22.
35. Vieweg WV. New generation antipsychotic drugs and Q–Tc interval prolongation. Prim Care Companion J Clin Psychiat 2003; 5: 205–15.
36. Vieweg WV, Schneider RK, Wood MA. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiat Scand 2005; 112: 318–22.
37. Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 2000; 49 (Suppl. 1): s57–60.
38. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 58–77.
39. Wong YWJ, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001; 21: 89–93.

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Материал для специалистов

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Материал для специалистов

Con-Med Passport